Pharmaceutically acceptable salt of 1-aryl-or 1-alkylsulfonyl-heterocyclylbenzazole as 5-hydroxytryptamine-6 ligand

Abstract

The present invention provides a pharmaceutically acceptable salt of a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor. A is C, CR10 or N; X is CR11 or N; Y is CR7 or N with the proviso that when X is N, then Y must be CR7; R1 is H, C1-C6alkylcarbonyl, C1-C6alkoxycarbonyl or an C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl or cycloheteroalkyl group each optionally substituted; R2, R3, R4, R5 and R6 are each independently H, halogen, OH or an optionally substituted C1-C6alkyl group; R7 and R11 are each independently H, halogen or an C1- C6alkyl, aryl, heteroaryl or C1-C6alkoxy group each optionally substituted; R8 is an C1-C6alkyl, aryl or heteroaryl group each optionally substituted; R9 is H, halogen or an C1-C6alkyl, C1-C6alkoxy, C2- C6alkenyl, aryl or heteroaryl group each optionally substituted; R10 is H, OH or an optionally substituted C1-C6alkoxy group; m is an integer of 1, 2 or 3; n is 0 or an integer of 1, 2 or 3; and − represents a single bond or a double bond.